Evaluating the activity of temsirolimus in neuroendocrine cancer.
O'Donnell
P H
PH
Ratain
M J
MJ
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D018450:Disease Progression; D006801:Humans; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; C401859:temsirolimus; D020123:Sirolimus